We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Focusing on applications for off-patent drugs is one way to eradicate the backlog of generic drug applications at the Office of Generic Drugs (OGD), according to a top FDA official.